The Biogen Kenneth Murray dejo un Legado :
Don Seiffert
Associate Editor MHT-
Boston Business Journal
Email
When Kenneth Murray, a professor at the University of Edinburgh in the 1970s, was involved in the founding of a company that later became Biogen Idec (Nasdaq: BIIB), was criticized by his peers as engaging in "activities repugnant. "
Phillip Sharp, a 1993 Nobel molecular biologist and co-founder of Biogen in 1978, along with Murray, told Mass High Tech that even here in the U.S., it was rare that a researcher is involved in the industry, although not was another way for drugs that are available for patients.
"There were few, if any, the MIT faculty involved in biotechnology at all" he said. "In fact, there were only invented the word."
Murray died earlier this month at age 82 at his home in Edinburgh, but the lives of patients who have saved and improved through the company he helped create will not be soon forgotten. Sharp, who is 69 years old and lives in Newton, Massachusetts, says he knew Murray in the 1970s because they were scientists working on recombinant DNA and genetics, and they met at international meetings. They, along with six others, co-founder of Biogen based on two initial drugs: interferon alpha for certain types of leukemia and hepatitis C, and hepatitis B vaccine, which is based on the investigation of Murray.
The hepatitis B vaccine Biogen was approved for use in 1982 and formed the revenue stream Biogen earlier, according to a brief biography written by Biogen. Before that, the vaccine was available, but very limited, and it had to be done with the blood of hepatitis B. Murray has found a way to create synthetically, and the resulting patent was cited in 2002 by IP Worldwide magazine as one of the 10 patents that changed the world, according to the company
Don Seiffert
Associate Editor MHT-
Boston Business Journal
When Kenneth Murray, a professor at the University of Edinburgh in the 1970s, was involved in the founding of a company that later became Biogen Idec (Nasdaq: BIIB), was criticized by his peers as engaging in "activities repugnant. "
"There were few, if any, the MIT faculty involved in biotechnology at all" he said. "In fact, there were only invented the word."
Murray died earlier this month at age 82 at his home in Edinburgh, but the lives of patients who have saved and improved through the company he helped create will not be soon forgotten. Sharp, who is 69 years old and lives in Newton, Massachusetts, says he knew Murray in the 1970s because they were scientists working on recombinant DNA and genetics, and they met at international meetings. They, along with six others, co-founder of Biogen based on two initial drugs: interferon alpha for certain types of leukemia and hepatitis C, and hepatitis B vaccine, which is based on the investigation of Murray.
The hepatitis B vaccine Biogen was approved for use in 1982 and formed the revenue stream Biogen earlier, according to a brief biography written by Biogen. Before that, the vaccine was available, but very limited, and it had to be done with the blood of hepatitis B. Murray has found a way to create synthetically, and the resulting patent was cited in 2002 by IP Worldwide magazine as one of the 10 patents that changed the world, according to the company
No comments:
Post a Comment